Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$7.75
-0.09 (-1.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $43.2M · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.0B
P/E
77.5x
↑EV/EBITDA
28.7x
↑ROE
2.7%
↑Gross Margin
34.1%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.2%
FCF CAGR
+54.2%
FCF margin
18.1%
FCF / Net income
3.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $915.5M · net income $49.2M · FCF $165.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $915.5M | $915.5M | $980.2M | $1.16B | $1.04B |
| Net Income | $49.2M | $49.2M | $60.1M | $67.2M | $108.7M |
| EBITDA | $121.1M | $121.1M | $121.3M | $135.4M | $181.3M |
| EPS | 0.10 | 0.10 | 0.12 | 0.13 | 0.21 |
| Gross Margin | 34.1% | 34.1% | 30.6% | 31.1% | 29.3% |
| Operating Margin | 13.8% | 13.8% | 10.8% | 8.5% | 15.4% |
| Net Margin | 5.4% | 5.4% | 6.1% | 5.8% | 10.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
| Current Ratio | 3.02 | 3.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $165.4M | $165.4M | $25.7M | $43.2M | $45.1M |
| Returns | |||||
| ROE | 2.7% | 2.7% | 3.4% | 3.8% | 6.3% |
| Valuation | |||||
| P/E | 77.50 | 77.50 | 65.99 | 73.94 | 43.66 |
| EV/EBITDA | 28.71 | 28.71 | 29.63 | 33.89 | 24.05 |
| P/B | 2.16 | 2.16 | 2.21 | 2.85 | 2.76 |
| Growth & Yield | |||||
| Revenue Growth | -6.6% | -6.6% | -15.7% | 11.6% | — |
| EPS Growth | -18.0% | -18.0% | -10.6% | -38.2% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
92.5%
EPS terminal req.
$0.69
Spread vs growth
-110.5%
5Y implied EPS CAGR
53.9%
EPS terminal req.
$0.83
Spread vs growth
-71.9%
10Y implied EPS CAGR
30.1%
EPS terminal req.
$1.34
Spread vs growth
-48.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.1%
Start / end P/E
68.1x → 80.4x
EPS bridge
0.12 → 0.10
Residual
-3.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.